Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 15/20 | 1.00 |
| ▸ | DYRK3 | O43781 | 5/20 | 0.76 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.76 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.76 |
| ▸ | CDK2 | P24941 | 5/20 | 0.76 |
| ▸ | CDK9 | P50750 | 5/20 | 0.76 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.76 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.76 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.76 |
| ▸ | DYRK2 | Q92630 | 5/20 | 0.76 |
| ▸ | DYRK1B | Q9Y463 | 5/20 | 0.76 |
| ▸ | CLK1 | P49759 | 1/20 | 0.76 |
| ▸ | CLK2 | P49760 | 1/20 | 0.76 |
| ▸ | CLK3 | P49761 | 1/20 | 0.76 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20485677 | 1.00 | FYN (1.00) | FYNDYRK3CCNT1CCNA2CDK2 | |
| SCHEMBL1053482 | 1.00 | FYN (1.00) | FYNDYRK3CCNT1CCNA2CDK2 | |
| SCHEMBL30521808 | 1.00 | FYN (1.00) | FYNDYRK3CCNT1CCNA2CDK2 | |
| SCHEMBL2946043 | 0.88 | FYN (0.79) | FYNDYRK3CCNT1CCNA2CDK2 | |
| SCHEMBL2946453 | 0.84 | FYN (0.79) | FYNDYRK3CCNT1CCNA2CDK2 | |
| SCHEMBL2941590 | 0.83 | FYN (0.75) | FYNDYRK3CCNT1CCNA2CDK2 | |
| SCHEMBL2947491 | 0.83 | FYN (0.77) | FYNDYRK3CCNT1CCNA2CDK2 | |
| SCHEMBL20485745 | 0.83 | FYN (1.00) | FYNDYRK3CCNT1CCNA2CDK2 | |
| SCHEMBL20485748 | 0.83 | FYN (1.00) | FYNDYRK3CCNT1CCNA2CDK2 | |
| SCHEMBL2947495 | 0.83 | FYN (0.77) | FYNDYRK3CCNT1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180250297-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | Pathways Neuro Pharma, Inc. | 2018-09-06 | — | — | US | claimed |
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | BIOGEN IDEC MA INC. (US) | 2011-01-27 | — | — | US | claimed |
| US-10688093-B2 | Methods, compositions, and uses of novel Fyn kinase inhibitors | Pathways Neuro Pharma, Inc. | 2020-06-23 | — | — | US | disclosed |
| US-20180250297-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | Pathways Neuro Pharma, Inc. | 2018-09-06 | — | — | US | disclosed |
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | BIOGEN IDEC MA INC. (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021513-A1 | MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | IRAK1, IRAK2, IRAK3 | FYN 666/4885DYRK3 2299/4885CCNT1 4289/4885 |
| US-20180250297-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | FYN, LCK, PTK2B | FYN 1/4885DYRK3 265/4885CCNT1 4406/4885 |
| US-10688093-B2 | Methods, compositions, and uses of novel Fyn kinase inhibitors | FYN, LCK, PTK2B | FYN 1/4885DYRK3 265/4885CCNT1 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.